Compare Quest Diagnostics Inc (DGX) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Manhattan Associates Inc — how do they compare? Quest Diagnostics Inc trades at $204.84 (market cap $22.80B), while Manhattan Associates Inc trades at $161.24 (market cap $9.38B). The key difference: Quest Diagnostics Inc is far larger — about 2.4× Manhattan Associates Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Manhattan Associates Inc pays none. Which is the better fit depends on your goals.
| DGX | MANH | |
|---|---|---|
Market Cap | $22.80B | $9.38B |
Sector | Health | Technology |
52-Week High | $216.02 | $227.94 |
52-Week Low | $166.42 | $120.88 |
Enterprise Value | $28.82B | $9.21B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
MANH trades at $158.31, up 2.2% today, with a bullish technical outlook supported by moving averages and strong quarterly EPS beats. The company maintains robust profitability with a 19.68% net margin and 96.24% ROE, though valuation multiples like P/E of 44.43 are elevated. Recent news highlights ongoing legal investigations but also cloud growth initiatives.
Outlook remains positive with a $192.80 analyst price target implying 22% upside, but risks include high valuation sensitivity, legal overhang from fiduciary investigations, and competitive pressures in supply chain software. Earnings momentum and institutional support provide near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
